MIAMI–(BUSINESS WIRE)–Elevate ENT Partners (“Elevate”), a leading management support organization (“MSO”) of ear, nose, and throat (“ENT”) practices nationwide, announced it has acquired North Florida Center for Otolaryngology (“North Florida ENT”). …
Author: Business Wire
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
INGELHEIM & JENA, Germany–(BUSINESS WIRE)–Boehringer Ingelheim and ZEISS Medical Technology announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and prevent vision loss for peopl…
Lassen Therapeutics Presents Preclinical Data on LASN01, an Anti-IL-11 Receptor Antibody in Development for Treatment of Thyroid Eye Disease at the American Thyroid Association 2023 Annual Meeting
SAN DIEGO–(BUSINESS WIRE)–Lassen Therapeutics, a clinical stage biotechnology company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R; LASN01) as a potential treatment for fibro-inflammatory diseases includin…
NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present …
Mogrify Extends Series A Financing to $46 Million USD
CAMBRIDGE, England–(BUSINESS WIRE)–Mogrify Limited (Mogrify®), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Serie…
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at American Thyroid Association (ATA) 2023.
Bausch + Lomb Completes Acquisition of XIIDRA®
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic…
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health, Inc.” to “Harrow, Inc.” to align with the Company’…
AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™: Expert Resource for FDA Approval Status of Specialty Pharmaceuticals and Cell & Gene Therapies
BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™: Expert Resource for FDA Approval Status of Specialty Pharmaceuticals & CGT
LumiThera erhält Zuschussbescheid vom National Eye Institute für einjährige Verlängerung von LIGHTSITE III, der zweijährigen US-amerikanischen, multizentrischen klinischen Studie über die Behandlung von trockener altersbedingter Makuladegeneration
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., ein Medizintechnikunternehmen, das Photobiomodulation (PBM) zur Behandlung von Augenschäden und -krankheiten anbietet, gab heute bekannt, dass es als kleines Unternehmen mit innovativer Forschungsarbeit (SBIR) …
LumiThera riceve l'avviso di aggiudicazione della sovvenzione del National Eye Institute a sostegno dell'estensione del 3o anno del progetto di ricerca LIGHTSITE III, lo studio clinico multicentrico statunitense per il trattamento della…
SEATTLE–(BUSINESS WIRE)– LumiThera riceve l’avviso di aggiudicazione della sovvenzione del National Eye Institute a sostegno dell’estensione del 3o anno del progetto di ricerca LIGHTSITE III, lo studio clinico multicentrico statunitense per il tratt…
LumiThera ontvangt aankondiging van toekenning van een subsidie van het National Eye Institute ter ondersteuning van een verlenging van 3 jaar van LIGHTSITE III, het Amerikaanse multicenter klinische onderzoek voor de behandeling van droge…
SEATTLE–(BUSINESS WIRE)– LumiThera ontvangt aankondiging van toekenning van een subsidie van het National Eye Institute ter ondersteuning van een verlenging van 3 jaar van LIGHTSITE III, het Amerikaanse multicenter klinische onderzoek voor de behand…
LumiThera annonce l’attribution d’une subvention du National Eye Institute pour la prolongation pour une troisième année de LIGHTSITE III, l’essai clinique multicentrique américain pour le traitement de la dégénérescence maculaire sèche liée à l’âge
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., société de dispositifs médicaux commercialisant un traitement par photobiomodulation (PBM) pour les troubles et maladies oculaires, a annoncé aujourd’hui qu’elle était bénéficiaire d’une subvention de phase II …
LumiThera recibe aviso de adjudicación de una subvención del Instituto Nacional del Ojo para apoyar una extensión del tercer año de LIGHTSITE III, el ensayo clínico multicéntrico estadounidense para el tratamiento de la degeneración macular seca…
SEATTLE–(BUSINESS WIRE)– LumiThera recibe aviso de adjudicación de una subvención del Instituto Nacional del Ojo para apoyar una extensión del tercer año de LIGHTSITE III, el ensayo clínico multicéntrico estadounidense para el tratamiento de la dege…
Global LASIK Eye Surgery Devices Market to 2028 with Johnson & Johnson, ZEISS Group, Alcon, Bausch + Lomb, and Ziemer Ophthalmic Systems Dominating – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global LASIK Eye Surgery Devices Market” report has been added to ResearchAndMarkets.com’s offering. Global LASIK eye surgery devices market is projected to reach a value of $3.7 billion by 2028 from $2.7 billion in 2023, …
LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera announced it is a recipient of a small business innovative research grant of ~$2.3M in funding from the NIH and the NEI.
PPG, Flō-Optics announce exclusive supplier agreement for first digitally applied optical coatings
PITTSBURGH–(BUSINESS WIRE)–PPG and Flō-Optics announce exclusive supplier agreement for first digitally applied optical coatings.
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
NASHVILLE, Tenn.–(BUSINESS WIRE)–Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an exclusive development and license agreement with Cat…
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY EYE ILLUMINATIONS, a new line of hypoall…
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Ghe…